Business Description
Nabriva Therapeutics PLC
NAICS : 325414
SIC : 2836
ISIN : IE000OZRGNV6
Description
Financial Strength
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 4.04 | |||||
Equity-to-Asset | -1.54 | |||||
Debt-to-Equity | -0.03 | |||||
Debt-to-EBITDA | -0.01 | |||||
Piotroski F-Score | 2/9 | |||||
Beneish M-Score | -22.22 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -20.1 | |||||
3-Year EBITDA Growth Rate | 57.5 | |||||
3-Year EPS without NRI Growth Rate | 57.6 | |||||
3-Year FCF Growth Rate | 61.6 | |||||
3-Year Book Growth Rate | -78.9 |
Momentum Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 24.95 | |||||
9-Day RSI | 22.74 | |||||
14-Day RSI | 24.81 | |||||
6-1 Month Momentum % | -20 | |||||
12-1 Month Momentum % | -70.83 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 0.38 | |||||
Quick Ratio | 0.38 | |||||
Cash Ratio | 0.08 | |||||
Days Inventory | 143.12 | |||||
Days Sales Outstanding | 112.72 | |||||
Days Payable | 66.88 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -103.8 |
Profitability Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | -16.64 | |||||
Operating Margin % | -169.17 | |||||
Net Margin % | -187.34 | |||||
FCF Margin % | -44.92 | |||||
ROE % | -642.51 | |||||
ROA % | -162.1 | |||||
ROIC % | -482.06 | |||||
ROC (Joel Greenblatt) % | -673.98 | |||||
ROCE % | -570.92 | |||||
Years of Profitability over Past 10-Year | 1 |
GF Value Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
EV-to-EBIT | 0.03 | |||||
EV-to-EBITDA | 0.03 | |||||
EV-to-Revenue | -0.06 | |||||
EV-to-Forward-Revenue | 0.06 | |||||
EV-to-FCF | 0.13 | |||||
Earnings Yield (Greenblatt) % | 3333.33 | |||||
FCF Yield % | 16.89 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Nabriva Therapeutics PLC Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | 28.191 | ||
EPS (TTM) (€) | -14.127 | ||
Beta | 0 | ||
Volatility % | 60 | ||
14-Day RSI | 24.81 | ||
14-Day ATR (€) | 0.08416 | ||
20-Day SMA (€) | 1.1315 | ||
12-1 Month Momentum % | -70.83 | ||
52-Week Range (€) | 0.186 - 8.25 | ||
Shares Outstanding (Mil) | 3.2 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 2 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Nabriva Therapeutics PLC Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Nabriva Therapeutics PLC Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
Nabriva Therapeutics PLC Frequently Asked Questions
What is Nabriva Therapeutics PLC(FRA:NTY)'s stock price today?
When is next earnings date of Nabriva Therapeutics PLC(FRA:NTY)?
Does Nabriva Therapeutics PLC(FRA:NTY) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |